Strong Buy Rating for Cidara Therapeutics: CD388’s Revolutionary Potential in Flu Treatment and Beyond

In a report released today, Stephen Brozak from WBB Securities maintained a Buy rating on Cidara Therapeutics (CDTX – Research Report), with a price target of $45.00.

Stephen Brozak’s rating is based on the promising potential of Cidara Therapeutics’ lead candidate, CD388, which aims to revolutionize flu treatment. CD388 offers a broad-spectrum antiviral approach that provides universal, season-long protection against all known strains of influenza with a single administration. This innovation could significantly reduce the healthcare burden associated with flu by decreasing the number of infections, hospitalizations, and deaths.
Moreover, the technology behind CD388 has the potential to extend beyond flu treatment, with applications in solid cancer therapies and other diseases. The company’s focus on protecting the most vulnerable populations in the U.S. further underscores the societal impact of their work. Given these factors, Brozak maintains a Strong Buy rating and reaffirms a 12-month price target of $45.00 for Cidara Therapeutics.

In another report released on May 27, Citizens JMP also reiterated a Buy rating on the stock with a $47.00 price target.